Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients. An ex vivo human study

Keyphrases

• Diabetic Patients 100%
• Human Studies 100%
• Bivalirudin 100%
• Unfractionated Heparin 100%
• Antithrombotic Effect 100%
• Eptifibatide 100%
• Percutaneous Coronary Intervention 62%
• Fibrin Deposition 37%
• Heparin 25%
• Thrombus Formation 25%
• Platelet Thrombus 25%
• Thrombus 25%
• Perfusion Study 25%
• High Risk 12%
• Aspirin 12%
• Clinical Characteristics 12%
• Clopidogrel 12%
• Patients with Diabetes 12%
• Porcine 12%
• Low Shear Rate 12%
• Rheologic 12%
• Thrombotic Complications 12%
• Perfusion Chamber 12%
• Dosing Regimen 12%
• Group by 12%
• Thrombogenic 12%
• Computerized Planimetry 12%
• Blood Thrombogenicity 12%
• Elective Percutaneous Coronary Intervention 12%
• Reduction Degree 12%
• Glycoprotein IIb-IIIa 12%
• High Shear Rate 12%
• Ex Vivo Perfusion 12%
• Tunica Media 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Anticoagulant Agent 100%
• Diabetes Mellitus 100%
• Heparin 100%
• Bivalirudin 100%
• Human Study 100%
• Eptifibatide 100%
• Thrombus 75%
• Acetylsalicylic Acid 12%
• Clopidogrel 12%
• Thrombogenicity 12%
• Pig 12%
• Fibrinogen Receptor 12%

Biochemistry, Genetics and Molecular Biology

• Heparin 100%
• Human Study 100%
• Eptifibatide 100%
• Perfusion 37%
• Fibrin Deposition 37%
• Coagulation System 25%
• Platelet 25%
• Clopidogrel 12%
• Shear Rate 12%
• Pig 12%
• Glycoprotein IIb/IIIa 12%